Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

66 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients.
Ugo V, Tondeur S, Menot ML, Bonnin N, Le Gac G, Tonetti C, Mansat-De Mas V, Lecucq L, Kiladjian JJ, Chomienne C, Dosquet C, Parquet N, Darnige L, Porneuf M, Escoffre-Barbe M, Giraudier S, Delabesse E, Cassinat B; French Intergroup of Myeloproliferative disorders. Ugo V, et al. Among authors: parquet n. PLoS One. 2010 Jan 26;5(1):e8893. doi: 10.1371/journal.pone.0008893. PLoS One. 2010. PMID: 20126644 Free PMC article.
High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a.
Kiladjian JJ, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S, Menot ML, Massonnet G, Dutel JL, Ghomari K, Rousselot P, Grange MJ, Chait Y, Vainchenker W, Parquet N, Abdelkader-Aljassem L, Bernard JF, Rain JD, Chevret S, Chomienne C, Fenaux P. Kiladjian JJ, et al. Among authors: parquet n. Blood. 2006 Sep 15;108(6):2037-40. doi: 10.1182/blood-2006-03-009860. Epub 2006 May 18. Blood. 2006. PMID: 16709929 Free article. Clinical Trial.
Mutations in exon 12 of JAK2 are mainly found in JAK2 V617F-negative polycythaemia vera patients.
Kouroupi E, Zoi K, Parquet N, Zoi C, Kiladjian JJ, Grigoraki V, Vainchenker W, Lellouche F, Marzac C, Schlageter MH, Dosquet C, Scott LM, Fenaux P, Loukopoulos D, Chomienne C, Cassinat B. Kouroupi E, et al. Among authors: parquet n. Br J Haematol. 2008 Aug;142(4):676-9. doi: 10.1111/j.1365-2141.2008.07223.x. Epub 2008 May 22. Br J Haematol. 2008. PMID: 18503583 Free article. No abstract available.
Anemia and hemodilution: analysis of a single center cohort based on 2,858 red cell mass measurements.
Drevon L, Maslah N, Soret-Dulphy J, Dosquet C, Ravdan O, Vercellino L, Belkhodja C, Parquet N, Brignier AC, Schlageter MH, Cassinat B, Kiladjian JJ, Chomienne C, Giraudier S. Drevon L, et al. Among authors: parquet n. Haematologica. 2021 Apr 1;106(4):1167-1171. doi: 10.3324/haematol.2020.249409. Haematologica. 2021. PMID: 32586907 Free PMC article. No abstract available.
Impact of NFE2 mutations on AML transformation and overall survival in patients with myeloproliferative neoplasms.
Marcault C, Zhao LP, Maslah N, Verger E, Daltro de Oliveira R, Soret-Dulphy J, Cazaux M, Gauthier N, Roux B, Clappier E, Parquet N, Dosquet C, Réa D, Zini JM, Vainchenker W, Raffoux E, Giraudier S, Kiladjian JJ, Cassinat B, Benajiba L. Marcault C, et al. Among authors: parquet n. Blood. 2021 Nov 25;138(21):2142-2148. doi: 10.1182/blood.2020010402. Blood. 2021. PMID: 33945619 Free article. No abstract available.
Clinical features and genomic landscape of myeloproliferative neoplasm (MPN) patients with autoimmune and inflammatory diseases (AID).
Elessa D, Zhao LP, de Oliveira RD, Maslah N, Soret-Dulphy J, Verger E, Marcault C, Parquet N, Fenaux P, Adès L, Raffoux E, Giraudier S, Fain O, Cassinat B, Kiladjian JJ, Mekinian A, Benajiba L. Elessa D, et al. Among authors: parquet n. Leukemia. 2023 Aug;37(8):1741-1744. doi: 10.1038/s41375-023-01967-0. Epub 2023 Jul 11. Leukemia. 2023. PMID: 37433887 No abstract available.
Thrombocytapheresis and sequential chemotherapy for extreme symptomatic thrombocytosis secondary to myelofibrosis: a case report.
Debureaux PE, Brignier A, Soret-Dulphy J, Réa D, Michonneau D, Peffault de Latour R, Sicre de Fontbrune F, Pagliuca S, Parquet N, Prata HP, Marouf A, Xhaard A, Kiladjian JJ, Socié G, Robin M. Debureaux PE, et al. Among authors: parquet n. Ann Hematol. 2020 Apr;99(4):897-898. doi: 10.1007/s00277-020-03948-0. Epub 2020 Feb 7. Ann Hematol. 2020. PMID: 32030449 No abstract available.
APRIL levels are associated with disease activity in human chronic graft-versus-host disease.
Chasset F, de Masson A, Le Buanec H, Xhaard A, de Fontbrune FS, Robin M, Rybojad M, Parquet N, Brignier AC, Coman T, Bengoufa D, Bergeron A, Peffault de Latour R, Bagot M, Bensussan A, Socié G, Bouaziz JD. Chasset F, et al. Among authors: parquet n. Haematologica. 2016 Jul;101(7):e312-5. doi: 10.3324/haematol.2016.145409. Epub 2016 Mar 18. Haematologica. 2016. PMID: 26992945 Free PMC article. Clinical Trial. No abstract available.
Quality risk management of the chimeric antigen receptor T cell pharmaceutical circuit in one of the first qualified European centers.
Talarmin C, Kerob S, Cartier F, Madelaine I, Mukenyi S, Schwartz E, Boissel N, Baruchel A, Thieblemont C, Parquet N, Brignier A, Lesprit E, Desproges A, Magdelonnette L, Larghero J, Mebarki M. Talarmin C, et al. Among authors: parquet n. Cytotherapy. 2020 Dec;22(12):792-801. doi: 10.1016/j.jcyt.2020.06.009. Epub 2020 Jul 27. Cytotherapy. 2020. PMID: 32732084
66 results